Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NovaMed Buys China Rights for Cancer Pain Drug from Orexo

publication date: Jan 27, 2009

NovaMed Pharmaceuticals has signed a $5 million licensing and distribution agreement with Orexo that gives NovaMed the right to seek approval in China for Abstral, Orexo´s drug for breakthrough cancer pain. If the drug is approved, NovaMed will distribute Orexo in China. The agreement calls for an upfront payment, regulatory milestones and sales milestones. NovaMed will be responsible for the regulatory approval process including the necessary clinical studies. More details...

Stock Symbols: (STO: ORX) (NYSE: PFE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here